Literature DB >> 2306418

Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man.

K Brøsen1, F Davidsen, L F Gram.   

Abstract

The kinetics at a single oral dose (400 mg) of quinidine were studied in four extensive metabolizers (EM) and four poor metabolizers (PM) of sparteine. The clearance of quinidine by 3-hydroxylation was significantly lower in PM than in EM, but the difference was small (25-30%). This finding suggests that 3-hydroxylation, in part, is catalyzed by the same isoenzyme of cytochrome P450, P450db1 which oxidizes sparteine. Otherwise, no significant phenotypic differences in total or metabolic clearance were found and it is concluded that the metabolism of quinidine is largely carried out by P450 isoenzymes different from P450db1. A biexponential decline in the log plasma quinidine concentration vs time curves was observed in all subjects, and the mean elimination half-life was 11-12 h. This is about twice as long as generally reported in the literature.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2306418      PMCID: PMC1380092          DOI: 10.1111/j.1365-2125.1990.tb03628.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  23 in total

1.  Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers.

Authors:  T Leemann; P Dayer; U A Meyer
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

2.  Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs.

Authors:  S V Otton; T Inaba; W Kalow
Journal:  Life Sci       Date:  1984-01-02       Impact factor: 5.037

3.  A human cytochrome P-450 characterized by inhibition studies as the sparteine-debrisoquine monooxygenase.

Authors:  T Inaba; M Nakano; S V Otton; W A Mahon; W Kalow
Journal:  Can J Physiol Pharmacol       Date:  1984-07       Impact factor: 2.273

4.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

Authors:  D A Evans; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1980-04       Impact factor: 6.318

Review 5.  Clinical pharmacokinetics of quinidine.

Authors:  H R Ochs; D J Greenblatt; E Woo
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

6.  Oxidation of quinidine by human liver cytochrome P-450.

Authors:  F P Guengerich; D Müller-Enoch; I A Blair
Journal:  Mol Pharmacol       Date:  1986-09       Impact factor: 4.436

7.  Pharmacokinetics of quinidine and three of its metabolites in man.

Authors:  A Rakhit; N H Holford; T W Guentert; K Maloney; S Riegelman
Journal:  J Pharmacokinet Biopharm       Date:  1984-02

8.  Sparteine oxidation polymorphism in Denmark.

Authors:  K Brøsen; S V Otton; L F Gram
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1985-11

9.  Kinetics and electrocardiographic changes after oral 3-OH-quinidine in healthy subjects.

Authors:  S Vozeh; T Uematsu; T W Guentert; H R Ha; F Follath
Journal:  Clin Pharmacol Ther       Date:  1985-05       Impact factor: 6.875

10.  Sparteine oxidation is practically abolished in quinidine-treated patients.

Authors:  R Brinn; K Brøsen; L F Gram; T Haghfelt; S V Otton
Journal:  Br J Clin Pharmacol       Date:  1986-08       Impact factor: 4.335

View more
  11 in total

1.  Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant.

Authors:  Hayley S Brown; Kiyomi Ito; Aleksandra Galetin; J Brian Houston
Journal:  Br J Clin Pharmacol       Date:  2005-11       Impact factor: 4.335

2.  A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man.

Authors:  M D Nielsen; K Brøsen; L F Gram
Journal:  Br J Clin Pharmacol       Date:  1990-03       Impact factor: 4.335

3.  Pharmacokinetics of quinidine in male patients. A population analysis.

Authors:  C N Verme; T M Ludden; W A Clementi; S C Harris
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

4.  Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes.

Authors:  P Dalén; M Dahl; K Andersson; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

5.  The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone.

Authors:  Evan D Kharasch; Christine Hoffer; Dale Whittington
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

6.  Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition.

Authors:  A A Moghadamnia; A Rostami-Hodjegan; R Abdul-Manap; C E Wright; A H Morice; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

7.  Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics of quinine.

Authors:  S Wanwimolruk; S Chalcroft
Journal:  Br J Clin Pharmacol       Date:  1991-11       Impact factor: 4.335

8.  Quinidine but not quinine inhibits in man the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase.

Authors:  G Muralidharan; E M Hawes; G McKay; E D Korchinski; K K Midha
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

9.  Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism.

Authors:  F Nielsen; J U Rosholm; K Brøsen
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 10.  Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping.

Authors:  R T Coutts
Journal:  J Psychiatry Neurosci       Date:  1994-01       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.